MedTrace Logo

A Collaborative Trial of Niraparib to Evaluate Patients With Ovarian Cancer in the Expanded Access Program in Latin America

NCT05857397 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 64

Last updated 2025-02-12

No results posted yet for this study

Summary

Data from niraparib treatment is not available in real-world setting in Latin America. The present study aims to collect data from patients treated with niraparib within the Latin America Expanded Access Program (EAP) in clinical practice in Brazil and Argentina and who meet the eligibility criteria for this study, without additional intervention.

Conditions

Interventions

OTHER

Observational study

This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Latin American Cooperative Oncology Group

    lead OTHER

Principal Investigators

  • Angélica Nogueira Rodrigues · Latin American Cooperative Oncology Group

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-21
Primary Completion
2025-05-31
Completion
2025-05-31

Countries

  • Argentina
  • Brazil

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05857397 on ClinicalTrials.gov